Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease

Fábio G. Teixeira,Miguel M. Carvalho,Krishna M. Panchalingam,Ana J. Rodrigues,Bárbara Mendes‐Pinheiro,Sandra Anjo,Bruno Manadas,Leo A. Behie,Nuno Sousa,António J. Salgado,Bárbara Mendes-Pinheiro

DOI: https://doi.org/10.5966/sctm.2016-0071

2016-09-22

Stem Cells Translational Medicine

Abstract:Abstract Research in the last decade strongly suggests that mesenchymal stem cell (MSC)-mediated therapeutic benefits are mainly due to their secretome, which has been proposed as a possible therapeutic tool for the treatment of Parkinson's disease (PD). Indeed, it has been shown that the MSC secretome increases neurogenesis and cell survival, and has numerous neuroprotective actions under different conditions. Additionally, using dynamic culturing conditions (through computer-controlled bioreactors) can further modulate the MSC secretome, thereby generating a more potent neurotrophic factor cocktail (i.e., conditioned medium). In this study, we have characterized the MSC secretome by proteomic-based analysis, investigating its therapeutic effects on the physiological recovery of a 6-hydroxidopamine (6-OHDA) PD rat model. For this purpose, we injected MSC secretome into the substantia nigra (SNc) and striatum (STR), characterizing the behavioral performance and determining histological parameters for injected animals versus untreated groups. We observed that the secretome potentiated the increase of dopaminergic neurons (i.e., tyrosine hydroxylase-positive cells) and neuronal terminals in the SNc and STR, respectively, thereby supporting the recovery observed in the Parkinsonian rats’ motor performance outcomes (assessed by rotarod and staircase tests). Finally, proteomic characterization of the MSC secretome (through combined mass spectrometry analysis and Bioplex assays) revealed the presence of important neuroregulatory molecules, namely cystatin C, glia-derived nexin, galectin-1, pigment epithelium-derived factor, vascular endothelial growth factor, brain-derived neurotrophic factor, interleukin-6, and glial cell line-derived neurotrophic factor. Overall, we concluded that the use of human MSC secretome alone was able to partially revert the motor phenotype and the neuronal structure of 6-OHDA PD animals. This indicates that the human MSC secretome could represent a novel therapeutic for the treatment of PD.

cell & tissue engineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment of Parkinson's Disease (PD), especially exploring the therapeutic potential of the secretome of mesenchymal stem cells (MSCs) in the Parkinson's disease model. Specifically, the study aims to verify whether the MSC secretome can reverse the behavioral and neuronal structural damage in the rat model of Parkinson's disease and explore its underlying neuroprotective mechanisms.

### Main research questions

1. **The influence of MSC secretome on the brain structure and behavior of Parkinson's disease model rats**:
- Researchers injected the MSC secretome into the substantia nigra pars compacta (SNc) and striatum (STR) of the 6 - hydroxydopamine (6 - OHDA) - induced Parkinson's disease rat model to evaluate its improvement effect on Parkinson's disease symptoms.

2. **The neuroprotective effect of MSC secretome**:
- Through behavioral tests (such as the RotaRod test, the Staircase test, etc.) and histological analysis (such as the change in the number of tyrosine hydroxylase - positive cells), evaluate the protective effect of the MSC secretome on dopaminergic neurons and its influence on the recovery of motor function.

3. **Identification of key neuromodulatory molecules in MSC secretome**:
- Use proteomics techniques (such as mass spectrometry analysis and Bioplex detection) to identify key molecules in the MSC secretome that may be involved in neuroprotection, such as cystatin C, glia - derived nexin, galectin - 1, pigment epithelium - derived factor, vascular endothelial growth factor (VEGF), brain - derived neurotrophic factor (BDNF), interleukin - 6 (IL - 6) and glial cell - derived neurotrophic factor (GDNF), etc.

### Conclusions

Studies have shown that the MSC secretome can partially reverse the motor phenotype and neuronal structural damage in the 6 - OHDA - induced Parkinson's disease rat model, indicating that the MSC secretome may be a new therapy for Parkinson's disease. These findings provide a theoretical basis for future Parkinson's disease treatment strategies based on extracellular therapies.

### Key formulas and terms

- **6 - OHDA**: 6 - hydroxydopamine, a neurotoxin used to induce animal models of Parkinson's disease.
- **TH - positive cells**: Tyrosine hydroxylase - positive cells, used to mark dopaminergic neurons.
- **RotaRod test**: A test used to evaluate the motor coordination ability of animals.
- **Staircase test**: A test used to evaluate the forelimb use and fine motor function of animals.

Through these experimental designs and analysis methods, researchers have revealed the potential value of the MSC secretome in the treatment of Parkinson's disease.